protein kinase C alphaGenealiases: AAG6 · PKC-alpha · PKCA · PKCI+/- · PKCalpha
Q-omics provides the consensus-scored PRKCA profile across patient tissues and cancer cell-line models. PRKCA expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRKCA is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PRKCA protein abundance shows 25,323 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where PRKCA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCA survival associations across molecular data types. PRKCA RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCA RNA expression–survival associations across cancer types. High PRKCA expression shows unfavorable associations in UVM, CESC, MESO and LUSC, but favorable associations in ACC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRKCA RNA expression.
This table summarizes PRKCA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRKCA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCA shows lower tumor expression in KIRC, THCA, UCEC and BLCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PRKCA RNA expression in tumor versus normal tissue (log2 FC = +0.980, t-test p < 0.001).
This table shows molecular features associated with PRKCA in patient tissues and cancer cell lines. In patient samples, PRKCA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
